Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.49
-0.11 (-1.96%)
At close: Oct 29, 2025, 4:00 PM EDT
5.45
-0.04 (-0.73%)
After-hours: Oct 29, 2025, 6:45 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$582,526
Market Cap
301.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Dec 31, 2020 | 41 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CADL News
- 13 days ago - Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - GlobeNewsWire
- 15 days ago - Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - GlobeNewsWire
- 15 days ago - Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PRNewsWire
- 15 days ago - Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - GlobeNewsWire
- 16 days ago - Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
- 26 days ago - Candel Therapeutics to Present at the SITC 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 6 weeks ago - Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire